Expression of c‑MET, EGFR and HER‑2 in gastric adenocarcinoma and their correlation with clinicopathological features and prognosis

Nian Rui,Li Wanjun,Li Weihua

Electronic Journal of Metabolism and Nutrition of Cancer ›› 2022, Vol. 9 ›› Issue (1) : 61-65.

PDF(1090 KB)
PDF(1090 KB)
Electronic Journal of Metabolism and Nutrition of Cancer ›› 2022, Vol. 9 ›› Issue (1) : 61-65.

Expression of c‑MET, EGFR and HER‑2 in gastric adenocarcinoma and their correlation with clinicopathological features and prognosis

  • Nian Rui,Li Wanjun,Li Weihua
Author information +
History +

Abstract

Objective To investigate the expression of c⁃MET, EGFR and HER⁃2 in gastric adenocarcinoma and their correlation with clinicopathological features and prognosis. Method From January 2016 to January 2018, 87 patients with gastric adenocarcinoma who underwent radical gastrectomy from the 3201 Hospital Affiliated toMedical College of Xi'an Jiaotong University were selected as the research objects.The expressions of c⁃MET,EGFR and HER⁃2 proteins in tissues were detected by immunohistochemical method, and their correlations with Ki⁃67 protein and clinicopathological features were analyzed.They were dividedinto positive group and negative group (37 casesin c⁃MET positive group and 50 cases in c⁃MET negative group). There were 33 cases in EGFR positive group and 54 cases in EGFR negative group. There were 39 cases in HER⁃2 positive group and 48 cases in HER⁃2 negative group.The recurrence free survival rate and overall survival rate were compared among the groups. ResultIn the pathological characteristics of the patients, the difference in the degree of differentiation,TNM stage, lymph node metastasis, distant metastasis, and tumor thrombus positive rate of c⁃MET, EGFR and HER⁃2 protein was statistically significant(P<0.05). The positive expression of c⁃MET, EGFR and HER⁃2 protein was positively correlated with the positive expression of Ki⁃67 protein (r=0.319, 0.338, 0.374;P<0.05).After 3 years of follow⁃up, 31 patients died andthe survival rate was 64.37%; 31 patients relapsed, and the recurrence⁃free survival rate was 64.37%. The median survival time of c⁃MET, EGFR and HER⁃2 positive group were 19.95, 19.28 and 21.49months, andthe median survivaltime of negative group were 33.84, 33.10 and 33.26months,respectively.The median recurrence⁃free survival time of c⁃MET, EGFR and HER⁃2 positive group were 14.59, 13.84 and 15.35months, and the negative group were 27.83, 27.37 and 27.57 months. The recurrence⁃free survival rate and overall survival rate of c⁃MET, EGFR and HER⁃2 positive group were lower than those of negative expression group (P<0.05). Positive EGFR protein is an independent prognostic factor affecting the overall survival of gastric adenocarcinoma (RR=4.278, 95%CI=2.099-8.713, P<0.05). Conclusion The expression of c⁃MET, EGFR and HER⁃2 protein in gastric adenocarcinoma was related to the degree of differentiation, depth of invasion,TNM stage, lymph node metastasis, distant metastasis and tumor thrombus. Patients with positive expression of c⁃MET, EGFR and HER⁃2 protein had higher recurrence rate, lower relapse free survival rate and overall survival rate, and worse prognosis. Positive EGFR protein is an independent prognostic factor that affects the overall survival of patients.

Key words

Gastric adenocarcinoma / Cellular?mesenchymal to epithelial transition factor / Epidermal growth factor receptor; Human epidermal growth factor receptor 2

Cite this article

Download Citations
Nian Rui,Li Wanjun,Li Weihua. Expression of c‑MET, EGFR and HER‑2 in gastric adenocarcinoma and their correlation with clinicopathological features and prognosis[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2022, 9(1): 61-65
PDF(1090 KB)

Accesses

Citation

Detail

Sections
Recommended

/